Compare Crispr Therapeutics AG (CRSP) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Plby Group Inc — how do they compare? Crispr Therapeutics AG trades at $53.37 (market cap $4.88B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Crispr Therapeutics AG is far larger — about 41.3× Plby Group Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Plby Group Inc for 24 Days on average.
| CRSP | PLBY | |
|---|---|---|
Market Cap | $4.88B | $118.21M |
Volume | 2,861,747 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $2.71 |
52-Week Low | $44.34 | $0.99 |
Typical Hold Time | 77 Days | 24 Days |
Enterprise Value | $3.30B | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
PLBY Group trades at $0.98, down 3.66% today, with a bearish technical signal from moving averages and oscillators. The company shows improving fundamentals with revenue stabilizing around $121 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent leadership appointments signal strategic growth initiatives, while analyst consensus remains strongly positive with 75% buy ratings.
The outlook suggests cautious optimism as PLBY transitions toward profitability, projected to reach net income of $283,000 in 2026. Key risks include high debt levels with 59.52% debt-to-asset ratio and persistent negative shareholder equity. The stock offers potential upside if turnaround execution succeeds, but remains vulnerable to operational challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
